Novavax (NVAX) Receivables (2010 - 2026)

Novavax's Receivables history runs 15 years deep, the most recent figure standing at $23.3 million for Q1 2026.

• In Q1 2026, Receivables fell 60.02% year-over-year to $23.3 million; the TTM figure through Mar 2026 stood at $23.3 million (down 60.02% YoY), while the FY2025 annual figure was $117.2 million, up 3.13% from the prior year.
• Receivables was $23.3 million for Q1 2026 at Novavax, down from $117.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $530.5 million in Q1 2022 to a low of $21.6 million in Q1 2024.
• Historically, Receivables has averaged $182.5 million across 5 years, with a median of $155.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 419.07% in 2022, then sank 86.13% in 2024.
• A 5-year view of Receivables shows it stood at $124.8 million in 2022, then surged by 152.96% to $315.7 million in 2023, then slumped by 63.99% to $113.7 million in 2024, then gained by 3.13% to $117.2 million in 2025, then sank by 80.13% to $23.3 million in 2026.
• The last three Receivables figures came in at $23.3 million (Q1 2026), $117.2 million (Q4 2025), and $39.4 million (Q3 2025), per Business Quant data.